REPL

Replimune Group Inc

REPL, USA

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

https://www.replimune.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
REPL
stock
REPL

Replimune Group (REPL) Price Target Increased by 10.52% to 12.82 Nasdaq

Read more →
REPL
stock
REPL

Replimune Group CEO Sushil Patel Sells 10,000 Shares TradingView

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$12.5714

Analyst Picks

Strong Buy

3

Buy

5

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

3.60

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-31.56 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-21.34 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

High

0.48

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 111.55% of the total shares of Replimune Group Inc

1.

Baker Bros Advisors LP

(14.1506%)

since

2025/06/30

2.

T. Rowe Price Associates, Inc.

(13.8609%)

since

2025/06/30

3.

BlackRock Inc

(7.3414%)

since

2025/06/30

4.

Redmile Group, LLC

(5.9762%)

since

2025/06/30

5.

US Small-Cap Growth II Equity Comp

(5.3991%)

since

2025/06/30

6.

T. Rowe Price New Horizons

(5.39%)

since

2025/07/31

7.

FCPM III SERVICES BV

(5.0088%)

since

2025/06/30

8.

Vanguard Group Inc

(4.4451%)

since

2025/06/30

9.

TANG CAPITAL MANAGEMENT LLC

(4.0996%)

since

2025/06/30

10.

State Street Corp

(3.1422%)

since

2025/06/30

11.

Boxer Capital Management, LLC

(2.833%)

since

2025/06/30

12.

RTW INVESTMENTS, LLC

(2.6456%)

since

2025/06/30

13.

Omega Fund Management LLC

(2.5305%)

since

2025/06/30

14.

Marshall Wace Asset Management Ltd

(2.3913%)

since

2025/06/30

15.

Sofinnova Ventures

(2.3144%)

since

2025/06/30

16.

T. Rowe Price Health Sciences

(2.2157%)

since

2025/07/31

17.

Vanguard Total Stock Mkt Idx Inv

(2.1849%)

since

2025/07/31

18.

Geode Capital Management, LLC

(2.0806%)

since

2025/06/30

19.

T. Rowe Price Integrated US Sm Gr Eq

(2.0494%)

since

2025/07/31

20.

iShares Russell 2000 ETF

(2.0271%)

since

2025/08/31

21.

T. Rowe Price Integrated US SmCapGrEq

(1.8987%)

since

2025/06/30

22.

T. Rowe Price New Horizons Tr-A

(1.666%)

since

2025/06/30

23.

Dimensional Fund Advisors, Inc.

(1.4931%)

since

2025/06/30

24.

Goldman Sachs Group Inc

(1.4315%)

since

2025/06/30

25.

Fidelity Select Biotechnology

(1.282%)

since

2025/07/31

26.

MPM Oncology Impact Management LP

(1.2604%)

since

2025/06/30

27.

SPDR® S&P Biotech ETF

(1.2414%)

since

2025/08/31

28.

Wellington Management Company LLP

(1.21%)

since

2025/06/30

29.

Morgan Stanley - Brokerage Accounts

(1.1808%)

since

2025/06/30

30.

Rosalind Advisors, Inc.

(1.153%)

since

2025/06/30

31.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9161%)

since

2025/07/31

32.

Fidelity Small Cap Index

(0.8468%)

since

2025/06/30

33.

iShares Russell 2000 Value ETF

(0.7523%)

since

2025/08/31

34.

iShares Biotechnology ETF

(0.4795%)

since

2025/08/31

35.

Fidelity Enhanced Small Cap ETF

(0.4763%)

since

2025/08/29

36.

Fidelity Extended Market Index

(0.4638%)

since

2025/07/31

37.

Artisan Non-U.S. Small-Mid Growth Comp

(0.4514%)

since

2025/06/30

38.

Artisan International Small-Mid Investor

(0.4514%)

since

2025/06/30

39.

Schwab US Small-Cap ETF™

(0.4099%)

since

2025/08/30

40.

Vanguard Russell 2000 ETF

(0.3976%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.6679

Latest Release

Date

2025-09-30

EPS Actual

-0.9

EPS Estimate

-0.84

EPS Difference

-0.06

Surprise Percent

-7.1429%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.